Download PDF
Geburtshilfe Frauenheilkd 2012; 72(12): 1088-1091
DOI: 10.1055/s-0032-1328070
Statement
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Transvaginal Ultrasound for Endometrial Carcinoma Screening – Current Evidence-based Data

Transvaginaler Ultraschall zum Screening auf Endometriumkarzinome – Evidenz-basierte Datenlage
E. Steiner
1   Department of Obstetrics and Gynaecology, GPR Clinical Centre Ruesselsheim
,
I. Juhasz-Bösz
2   Department of Obstetrics and Gynaecology, University of Saarland
,
G. Emons
3   Department of Obstetrics and Gynaecology, Georg-August-University of Goettingen
,
H. Kölbl
4   Department of Obstetrics and Gynaecology, Medical University of Vienna
,
R. Kimmig
5   Department of Obstetrics and Gynaecology, University of Duisburg-Essen
,
P. Mallmann
6   Department of Obstetrics and Gynaecology, Cologne University
,
für die AGO Uterus der DGGG › Author Affiliations
Further Information

Publication History

Publication Date:
19 December 2012 (online)

Also available at
   Permissions and Reprints

Abstract

The value of transvaginal ultrasound in gynaecological examinations is beyond dispute. But it is of particular forensic importance that the validity of this type of imaging with regard to the reliable detection of early-stage malignancy is properly understood. Vaginal ultrasound screening in asymptomatic patients for the early detection of endometrial carcinoma is not useful from a medical point of view, nor is it cost-efficient. However, even though the validity of transvaginal ultrasound for screening has currently not been proven, the method should still be an integral part of gynaecological examinations.

Zusammenfassung

Die Wertigkeit der transvaginalen Ultraschalluntersuchung im Rahmen der gynäkologischen Untersuchung ist unbestritten. Es ist aber von besonderer auch forensischer Bedeutung, dass die Aussagekraft dieses Untersuchungsverfahrens im Hinblick auf das sichere Erkennen einer Krebserkrankung im Frühstadium sinnvoll eingeordnet wird. Unter Kosten-Nutzen-Gesichtspunkten ist ein generelles Screening bei asymptomatischen Patientinnen nicht sinnvoll. Zwar kann die transvaginale Sonografie das Ziel als Screeninginstrument zum gegenwärtigen Zeitpunkt nicht erreichen kann, sie bleibt aber integraler Bestandteil der gynäkologischen Untersuchung.

Key words

transvaginal ultrasound - endometrial cancer - screening

Schlüsselwörter

transvaginaler Ultraschall - Endometriumkarzinom - Screening

Supporting Information

 

  • References

  • 1 Jacobs I, Gentry-Maharaj A, Burnell M et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011; 12: 38-48
    CrossrefPubMedGoogle Scholar
  • 2 Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24: 558-565
    CrossrefPubMedGoogle Scholar
  • 3 Gerber B, Krause A, Muller H et al. Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 2001; 37: 64-71
    CrossrefPubMedGoogle Scholar
  • 4 Horwitz RI, Feinstein AR, Horwitz SM et al. Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. Lancet 1981; 2: 66-68
    PubMedGoogle Scholar
  • 5 Smith-Bindman R, Kerlikowske K, Feldstein VA et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998; 280: 1510-1517
    CrossrefPubMedGoogle Scholar
  • 6 Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002; 99: 663-670
    CrossrefPubMedGoogle Scholar
  • 7 Clark TJ, Barton PM, Coomarasamy A et al. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG 2006; 113: 502-510
    CrossrefPubMedGoogle Scholar
  • 8 Timmermans A, Opmeer BC, Khan KS et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 160-167
    CrossrefPubMedGoogle Scholar
  • 9 Albring C, Baum E, Beckermann MJ et al. S3-Leitlinie: Hormontherapie in der Peri- und Postmenopause (HAT). AWMF-Leitlinien-Register 2009; Nr. 015/062.
    PubMedGoogle Scholar
  • 10 Lethaby A, Suckling J, Barlow D et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; (3) CD000402
    PubMedGoogle Scholar
  • 11 Van den Bosch T, Van Schoubroeck D, Ameye L et al. Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy. Am J Obstet Gynecol 2003; 188: 1249-1253
    CrossrefPubMedGoogle Scholar
  • 12 Van den Bosch T, Coosemans A, Morina M et al. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol 2012; 26: 257-266
    CrossrefPubMedGoogle Scholar
  • 13 Dreisler E, Stampe Sorensen S, Ibsen PH et al. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Ultrasound Obstet Gynecol 2009; 33: 102-108
    CrossrefPubMedGoogle Scholar
  • 14 Ferrazzi E, Zupi E, Leone FP et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol 2009; 200: 235.e1-235.e6
    PubMedGoogle Scholar
  • 15 Lee SC, Kaunitz AM, Sanchez-Ramos L et al. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 1197-1205
    CrossrefPubMedGoogle Scholar
  • 16 Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen therapy. Gynecol Oncol 2004; 94: 256-266
    CrossrefPubMedGoogle Scholar
  • 17 Garuti G, Cellani F, Centinaio G et al. Histopathologic behaviour of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol Oncol 2006; 101: 269-273
    CrossrefPubMedGoogle Scholar
  • 18 Singh MN, Stringfellow HF, Paraskevaidis E et al. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 2007; 33: 91-100
    CrossrefPubMedGoogle Scholar
  • 19 Gao W, Zhang LP, Feng LM. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen. Chinese Medical J 2011; 124: 2335-2339
    PubMedGoogle Scholar
  • 20 Bertelli G, Venturini M, Del Mastro L et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998; 47: 41-46
    CrossrefPubMedGoogle Scholar
  • 21 Gerber B, Krause A, Müller H et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-3470
    PubMedGoogle Scholar
  • 22 Fung MF, Reid A, Faught W et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003; 91: 154-159
    CrossrefPubMedGoogle Scholar
  • 23 Polin SA. The effect of tamoxifen on the genital tract. Cancer Imaging 2008; 8: 135-145
    CrossrefPubMedGoogle Scholar
  • 24 Markovitch O, Tepper R, Fishman A et al. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 2004; 95: 456-462
    CrossrefPubMedGoogle Scholar
  • 25 Weaver J, McHugo JM, Clark TJ et al. Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. Br J Radiol 2005; 78: 394-397
    CrossrefPubMedGoogle Scholar